Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

APREPITANT

APREPITANT

Standard Dose
32MG/4.4ML (7.2MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview APREPITANT is listed in Drugs@FDA under application 218851 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient APREPITANT Form and strength EMULSION;INTRAVENOUS - 32MG/4.4ML (7.2MG/ML) Sponsor MYLAN Submission history Latest submission status date: 2026-03-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview APREPITANT is listed in Drugs@FDA under application 218851 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient APREPITANT Form and strength EMULSION;INTRAVENOUS - 32MG/4.4ML (7.2MG/ML) Sponsor MYLAN Submission history Latest submission status date: 2026-03-05 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.